Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
POINT Biopharma
Biotech
Deadline for Point investors as data meets Lilly's expectations
Point investors now have phase 3 data to compare to Novartis’ results—and days to choose whether to cash out or reject Lilly's $1.4 billion offer.
Nick Paul Taylor
Dec 18, 2023 9:50am
Novartis, Lilly drive investor interest in radiopharmaceuticals
Dec 8, 2023 10:02am
How Novartis is disrupting Lilly's $1.4B radiotherapy plan
Dec 5, 2023 11:21am
Lilly enters radiopharmaceuticals with $1.4B Point Biopharma buy
Oct 3, 2023 9:43am
Lantheus pledges up to $2B for 2 of POINT's radiopharmaceuticals
Nov 14, 2022 9:50am
